High Court Refuses Pfizer Appeal Over Novartis Hemophilia IP
The U.S. Supreme Court on Monday declined to hear a Pfizer Inc. unit's argument that a lower court incorrectly upheld Novartis Vaccines & Diagnostics Inc.'s hemophilia drug patents based based on...To view the full article, register now.
Already a subscriber? Click here to view full article